Dr. Douglas Dieterich: “DDIs in the Evolving HCV Treatment Landscape”
Douglas Dieterich, MD, discusses assessment of potential drug-drug interactions with concomitant medications prior to starting HCV antiviral therapy and the ongoing monitoring for drug-drug interactions during therapy. This activity is intended for gastroenterologists, hepatologists, infectious disease specialists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with HCV. Learn more
Researchers Identify Potential Target for Treatment Among Patients With Type 2 Diabetes
Aug 04, 2022 View All Press Releases
Mount Sinai Researcher Receives Prestigious International Award
Jul 06, 2022 View All Press Releases
